Marinus Pharmaceuticals
Marinus Pharmaceuticals Logo
About Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutic products for patients with rare genetic epilepsies and other seizure disorders. Its lead product, ZTALMY (ganaxolone), is an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in both adult and pediatric populations. The company is also developing ganaxolone for other genetic epilepsy disorders, such as PCDH19-related epilepsy and tuberous sclerosis complex. Marinus Pharmaceuticals operates primarily in the United States and collaborates with partners to advance treatments for serious neurological and psychiatric conditions.
Address
5 Radnor Corporate Center, Suite 500 100 Matsonford Road
Radnor, 19087
United States
Year founded
2003
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Report inaccurate data
Request an update to help us keep the brand up-to-date.
